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Abstract
Objective. The EORTC QLQ-C30 is widely used for assessing quality of life in cancer. However, QLQ-C30 responses
cannot be incorporated in cost-utility analysis because they are not based on general population’s preferences, or
utilities. To overcome this limitation, the QLU-C10D, a cancer-specific utility algorithm, was derived from the QLQ-
C30. The aim of this study was to obtain Canadian population utility weights for the QLU-C10D. Methods.
Respondents from a Canadian research panel expressed their preferences for 16 choice sets in an online discrete
choice experiment. Each choice set consisted of two health states described by the 10 QLU-C10D domains plus an
attribute representing duration of survival. Using a conditional logit model, responses were converted into utility
decrements by evaluating the marginal rate of substitution between each QLU-C10D domain level with respect to
duration. Results. A total of 3,363 individuals were recruited. A total of 2,345 completed at least one choice set and
2,271 completed all choice sets. The largest utility decrements were associated with the worse levels of Physical
Functioning (20.24), Pain (20.18), Role Functioning (20.15), Emotional Functioning (20.12), and Nausea
(20.12). The remaining domains and levels had decrements of 20.05 to 20.09. The utility of the worst possible
health state was 20.15. Conclusion. Respondents from the general population were most concerned with generic
health domains, but Nausea and Bowel Problems also had an impact on the individual’s utility. It is unclear as to
whether cancer-specific domains will affect cost-utility analysis when evaluating cancer treatments; this will be tested
in the next phase of the study.
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Introduction
The pan-Canadian Oncology Drug Review within the
Canadian Agency for Drugs and Technology in Health
promotes rigorous and objective cancer drug reviews
through the use of clinical and economic evaluations, as
well as patient perspectives and experiences. For the eco-
nomic evaluation component of this process, cost-utility
analysis (CUA) is recommended to guide the prioritiza-
tion of new therapies, including cancer drugs, within a
constrained budget.1,2 In CUA, outcomes are expressed
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using quality-adjusted life years (QALYs). QALYs are
derived by adjusting life years by the quality of the sur-
vival time in a given health. This adjustment, referred to
as a utility index, represents a typical individual’s prefer-
ence for each health state, bounded at one (full health)
and zero (dead); negative values are possible indicating
states worse than dead. To facilitate comparability across
health states and conditions, conventionally, responses
to generic multi-attribute utility instruments (MAUIs)
afford utilities to be incorporated into CUA. These
instruments, such as the Health Utilities Index Mark 33
and EQ-5D,4 cover broad health dimensions pertaining
to, for example, mobility and self-care. Despite their wide
applicability, generic MAUIs may not be sensitive to
changes specific to issues that concern cancer patients.5
Instead, many researchers collect patient-reported out-
comes using disease-specific instruments. In the context
of cancer, the use of cancer-specific quality of life instru-
ments, such as the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life
Questionnaire–Core 30 (QLQ-C30)6 is widespread; in
2012, more than 9,000 QLQ-C30 user agreements were
signed for clinical trials and academic studies.7 However,
the QLQ-C30 was not originally designed to produce
utilities, which has limited its usefulness for priority set-
ting and resource allocation decisions.
Recently, the Multi-Attribute Utility in Cancer
(MAUCa) Consortium, comprising international research-
ers with expertise in psychometrics, health economics, and
oncology, facilitated the development of an algorithm to
derive cancer-specific utilities based on the QLQ-C30
instrument. This was achieved through extensive analysis
of QLQ-C30 data, applying psychometric criteria and
patient input to reduce the instrument’s original 30 items
to form the 10 domains of the QLU-C10D’s health state
classification system,8 and then developing a valuation
method based on discrete choice experiment (DCE) meth-
ods.9 The MAUCa Consortium’s goal is to provide a set
of country-specific utility scoring algorithms that can be
applied to data from the QLQ-C30 to generate utilities;
the use of identical valuation methods across countries cre-
ates a unique opportunity to explore predictors of health
outcome values (e.g., country, age, sex, education, and
health status) in the future. While Australia was the first
to produce country-specific utility weights for the QLU-
C10D,10 there is a need to inform cancer priority setting
and resource allocation decisions in other countries,
including Canada, with country-specific utility weights for
the QLU-C10D. The aim of this article is to produce
QLU-C10D utility weights for the Canadian general popu-
lation using the standard MAUCa DCE methods.
Methods
QLU-C10D Health State Classification System
The derivation of the QLU-C10D health state classifica-
tion system is described elsewhere.8 In brief, adapting
previously used methods,11 the MAUCa Consortium
identified core QLQ-C30 domains, confirmatory factor
analysis confirmed the QLQ-C30 measurement model,
and results from Rasch and psychometric analyses, as
well as patient preferences, guided item selection. The
QLU-C10D consists of 10 domains, which directly map
to 13 items of the QLQ-C30 (Table 1); all domains are
assessed during the past week. Nine of these domains are
described by the same four levels as for QLQ-C30 items:
not at all, a little, quite a bit, and very much. The
remaining domain—Physical Functioning—has more
complex levels (see Table 1). The name, QLU-C10D, has
been endorsed by the EORTC Quality of Life Group
Executive Committee: ‘‘QLU’’ indicates it is a utility
measure; ‘‘C’’ indicates its origin in the EORTC’s core
questionnaire; and ‘‘10D’’ indicates its 10 domains.8
Discrete Choice Experiment
The QLU-C10D health state classification system was
valued in the Canadian setting using the DCE methodol-
ogy developed for the Australian valuation. Details of
the experimental design and piloting of the valuation sur-
vey methodology have been reported previously.9,10 In
summary, respondents were presented with choice sets in
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Table 1 The QLU-C10D Health State Classification System
Dimension Level Stem Descriptor QLQ-C30 Item Scores
Physical
Functioninga,b
1 You have . . . No trouble taking a long walk
outside of the house
Item 2 (long walk) = 1
2 No trouble taking a short
walk outside of the house,
but at least a little trouble
taking a long walk
Item 3 (short walk) = 1
AND Item 2  2
3 A little trouble taking a short
walk outside of the house,
and at least a little trouble
taking a long walk
Item 3 = 2 AND
Item 2  2
4 Quite a bit or very much
trouble taking a short walk
outside the house
Item 3  3 AND
Item 2  2
Role Functioning 1 You are limited in pursuing
your work or other daily
activities . . .
Not at all Item 6 = 1
2 A little Item 6 = 2
3 Quite a bit Item 6 = 3
4 Very much Item 6 = 4
Social Functioninga,c 1 Your physical condition or
medical treatment interferes
with your social or family
life . . .
Not at all Items 26 AND 27 = 1
2 A little Items 26 OR 27 = 2c
3 Quite a bit Items 26 OR 27 = 3c
4 Very much Items 26 OR 27 = 4c
Emotional
Functioning
1 You feel depressed . . . Not at all Item 24 = 1
2 A little Item 24 = 2
3 Quite a bit Item 24 = 3
4 Very much Item 24 = 4
Pain 1 You have pain . . . Not at all Item 9 = 1
2 A little Item 9 = 2
3 Quite a bit Item 9 = 3
4 Very much Item 9 = 4
Fatigue 1 You feel tired . . . Not at all Item 18 = 1
2 A little Item 18 = 2
3 Quite a bit Item 18 = 3
4 Very much Item 18 = 4
Sleep 1 You have trouble sleeping . . . Not at all Item 11 = 1
2 A little Item 11 = 2
3 Quite a bit Item 11 = 3
4 Very much Item 11 = 4
Appetite 1 You lack appetite . . . Not at all Item 13 = 1
2 A little Item 13 = 2
3 Quite a bit Item 13 = 3
4 Very much Item 13 = 4
Nausea 1 You feel nauseated . . . Not at all Item 14 = 1
2 A little Item 14 = 2
3 Quite a bit Item 14 = 3
4 Very much Item 14 = 4
Bowel problemsa,c 1 You . . . Do not have constipation or
diarrhea at all
Items 16 AND 17 = 1
2 Have a little constipation or
diarrhea
Items 16 OR 17 = 2c
3 Have constipation or diarrhea
quite a bit
Items 16 OR 17 = 3c
4 Have constipation or diarrhea
very much
Items 16 OR 17 = 4c
Duration 1 You will live in this health
state for . . .
1 year, and then die Not applicable
2 2 years, and then die Not applicable
3 5 years, and then die Not applicable
4 10 years, and then die Not applicable
aThree dimensions of the QLU-C10D each involve two QLQ-C30 items.
bThe Physical Functioning dimension includes ‘‘long walk’’ and ‘‘short walk’’ from the QLQ-C30; for the DCE, the levels are determined
together, but were presented in the DCE survey separately, as shown in Figure 1.
cFor Social Functioning and Bowel Problems, the QLU-C10D level is determined by the maximum value of the two component items.
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which they had to choose between two health states, each
with a specified duration of life years. The experimental
design underpinning the DCE contained 11 attributes:
the 10 QLU-C10D domains and duration of survival.
However, to facilitate respondent comprehension of the
complex levels of the Physical Functioning domain, the
two component items, ‘‘long walk’’ and ‘‘short walk,’’
were presented separated in the valuation survey (Figure
1). Because the QLU-C10D contains a large number of
domains, the DCE experimental design was specified
such that only four of its domains differed in each choice
sets, and these were highlighted in yellow to reduce the
cognitive complexity of the choice task; this presentation
format was pilot-tested and found to be feasible.9
The QLU-C10D health state classification system has
410 possible health states: 960 choice sets were selected to
maximize statistical efficiency, and to estimate main
effects and all two-factor interactions involving duration.
A balanced incomplete block design constrained the
number of QLU-C10D domains that differed between
health states in any given choice set to four.9 Each
respondent randomly received 16/960 choice sets without
replacement; which option seen as Situation A or
Situation B was randomized within each choice set. The
order of the QLU-C10D domains was also randomized
for each respondent but the order was kept the same for
the respondent when completing the 16 choice sets.
Data Collection
Sampling and survey administration for all country-
specific valuations in the MAUCa Consortium were
undertaken by SurveyEngine, a company that specializes
in choice experiments.12 For this study, respondents over
18 years of age from the Canadian general population
were recruited from an online panel. Quota sampling
ensured age, sex, and province/territory of residence
aligned with the Canadian Census.13 While the determi-
nation of appropriate sample sizes in choice experiments
is difficult,14 the sample size was selected to exceed the
suggested 20 responses per choice set to estimate reliable
models.15
Figure 1 Example choice set from the discrete choice experiment valuation task.
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Respondents completed the following survey compo-
nents, in order: 1) self-reported health, assessed by the
General Health Question of the SF-3616 and the QLQ-
C306; 2) DCE valuation task; 3) DCE feedback (i.e., per-
ceived difficulty and clarity of, as well as the choice strat-
egy used in, the valuation task); 4) sociodemographic
characteristics; and 5) additional self-reported health,
assessed by the Kessler-1017 and the EQ-5D-5L.4 The
length of time the respondent transitions between survey
pages were recorded. The study protocol was approved
by the Research Ethics Board at BC Cancer and the
University of British Columbia (H15-03293).
Data Analysis
Sample Representation. The sample was characterized in
the terms of age, sex, province/territory of residence,
highest level of education, marital status, and self-
reported General Health Question. Chi-squared tests
assessed the study sample representation in comparison
to the Canadian general population.13 The mean time
spent on the whole survey and on the choice sets were
recorded. The aggregate mean responses to the QLU-
C10D, EQ-5D-5L, and Kessler-10, as well as the correla-
tion between QLU-C10D and EQ-5D-5L, were reported.
Choice inconsistencies were assessed by the frequencies
of respondents selecting one option among all choice sets
(e.g., all Situation A).
Utility Estimation. DCE responses were analyzed using
a functional form in which the QLU-C10D attribute lev-
els interacted with the duration variable18:
Uisj=aTIMEisj+bX
0
isjTIMEisj+ eisj, ð1Þ
where X
0
isj was a set of dummy variables relating to the
levels of the QLU-C10D health state presented in option
j and eisj was a random error term distributed indepen-
dently and identically normal. This approach has previ-
ously been used to estimate utilities from DCE data to
ensure consistency with standard QALY model restric-
tions14,18,19: 1) all health states converges as survival
duration tends to zero and 2) the relationship between
utility and time is constrained to be linear (i.e., constant
proportional time tradeoff).
The modelling approach followed that was used in the
Australian valuation study.10 First, a conditional logit
model was used to analyze the DCE responses (Model
1). A clustered sandwich estimator using the vce (cluster)
option in STATA adjusted the standard errors to allow
for intro-individual correlation as each respondent was
asked to consider 16 DCE choice sets. The impact of
moving away from one level of each domain is investi-
gated through two-factor interaction terms with the con-
tinuous duration term rather than through the main
effect (e.g., the effect of moving from level 1 to level 2 in
the Pain domain is determined by using a Pain level 2*
Duration interaction term). If non-monotonic ordering
was present between domain levels in the conditional
logit model, another conditional logit model was run
after collapsing non-monotonic domain levels (Model 2).
A log-likelihood ratio test assessed the model fit between
Model 1 and Model 2.
Results
Sample Characteristics and Representation
Respondents from the Canadian general population
entered the study (n= 3,956); of which, 3,421 consented to
participate in the study. From the pool of consented respon-
dents, n= 2,459 were considered eligible because they were
using the appropriately sized electronic device (n = 329
excluded) and their personal characteristics were not already
aligned with the quota sampling recruitment strategy (n =
633 excluded). The final analysis set included 2,345 respon-
dents: 74 completed at least one choice set and 2,271 com-
pleted all choice sets. Post hoc analysis showed that there
were no statistically significant differences between the eligi-
ble respondents (n = 2,459) and the final analysis set (n =
2,345) in terms of sex, age, province/territory of residence,
and language for which the survey was completed. Of the
2,271 respondents who completed the entire survey, the
median (interquartile range) to complete all choice sets and
demographics was 21 minutes 11 seconds (16 minutes 32
seconds). The completion of the 16 choice sets was 5 min-
utes 13 seconds (6 minutes 17 seconds).
The study sample differed statistically from the gen-
eral population in all measured characteristics except for
age, sex, and province/territory of residence (Table 2).
Compared with the general population, the sample con-
sisted of statistically more participants whose primary
language is English, completed college education, and
reported poorer health based on the General Health
Question. Table 3 presents the aggregate scores (mean 6
standard deviation [SD]) for the QLU-C10D (0.753 6
0.212), EQ-5D-5L (0.833 6 0.156), and the Kessler-10
(17.91 6 7.68). The QLU-C10D and EQ-5D-5L are
highly correlated at 0.773.
Utility Estimates
The conditional model revealed that respondents pre-
ferred additional life years (Table 4). All movements
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Table 2 Self-Reported Health and Sociodemographic Characteristics of the Sample Compared With Those of the Canadian
General Population
Question Level Number Proportion Population Valuea x2 Statistic P Value
Gender Male 1,120 0.48 0.48 0.17 0.92
Female 1,217 0.52 0.52
Other 8 0.03 Not reported
Age (years) 18–29 454 0.19 0.20 6.89 0.33
30–39 409 0.17 0.17
40–49 468 0.20 0.21
50–59 421 0.18 0.18
60–69 303 0.13 0.11
70 or older 290 0.12 0.13
Province or territory
of residence
Alberta 249 0.11 0.12 9.10 0.77
British Columbia 302 0.13 0.13
Manitoba 86 0.04 0.04
New Brunswick 53 0.02 0.02
Newfoundland and Labrador 35 0.02 0.02
Nova Scotia 62 0.03 0.03
Northwest Territory 1 0.00 0.00
Nunavut Territory 0 0.00 0.00
Ontario 911 0.39 0.39
Quebec 561 0.24 0.23
Prince Edward Island 13 0.01 0.00
Saskatchewan 69 0.03 0.03
Yukon Territory 3 0.00 0.00
Primary language
spoken at home
English 1,736 0.74 0.58 445.5 \0.01
French 541 0.23 0.22
Other 68 0.03 0.20
Marital status Single 728 0.32 0.28 65.2 \0.01
Legally married 924 0.41 0.48
In a common-law relationship 316 0.14 0.11
Separated, but still legally
married
59 0.03 0.03
Divorced 174 0.08 0.06
Widowed 79 0.04 0.06
Education level No certificate, diploma, or
degree
99 0.04 0.15 237.4 \0.01
High school certificate or
equivalent
549 0.24 0.24
Apprenticeship or trade
certificate or diploma
174 0.08 0.12
College, CEGEP, or other
non-university certificate or
diploma
666 0.29 0.20
University certificate or
diploma below the bachelor’s
level
226 0.10 0.05
University certificate, diploma,
or degree at bachelor’s level
or above
566 0.25 0.23
General health question Excellent 257 0.11 0.22 284.9 \ 0.01
Very good 800 0.34 0.38
Good 877 0.37 0.29
Fair 334 0.14 0.11
Poor 77 0.03
aRounding of proportions to two decimal places.
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away from ‘‘no problems’’ (level 1) in each of the
domains were valued negatively. With two exceptions,
incremental moves to the next worst domain level were
associated with an absolutely larger coefficient. The two
non-monotonicities were the worst two levels of the
Fatigue and Sleep domains. The model was reestimated
constraining the respective levels to be the same to
remove these non-monotonicities. The log-likelihood
ratio test indicated that there was no improvement in fit
between the unconstrained and constrained models
(x2 = 1.29, P = 0.52). As per the Australian QLU-
C10D valuation study,10 the estimates from the parsimo-
nious Model 2 (constrained) defined the Canadian value
set for the QLU-C10D.
Model 2 revealed that the Physical Functioning and
Pain domains most greatly affected the individual’s utility
function (Table 5); this was followed by Role Functioning,
Nausea, and Emotional Functioning. Sizeable decrements
were observed for Social Functioning and Bowel Problems;
smaller decrements for Fatigue and Sleep.
Three post hoc analyses were conducted. First, left-right
bias appears to be present even though the order which the
respondents view the scenarios was randomized. However,
the left-right bias did not have an impact on the resulting
Canadian value set for the QLU-C10D. Second, the incon-
sistencies in the choice sets were tested by exploring the fre-
quencies of which a respondent would select Situation As
and Situation Bs among all 16 choice sets. We observed
that approximately 1% of respondents ‘‘clicked through,’’
selecting the majority of Situation As or Situation Bs.
These respondents were not deleted from analysis as this
may result in the removal of valid preferences, induce sam-
ple selection bias, and reduce the statistical efficiency and
power of the estimated choice models.20 Third, the sample
was reweighted to better reflect the demographic character-
istics of the Canadian general population. We observed no
differences in the utility decrements for the QLU-C10D
domains. Details from the post hoc analyses are available
from the authors.
QLU-C10D Utility Calculation
As per the conditions set by the EORTC Quality of Life
Group, the QLU-C10D cannot be used as a standalone
instrument. The Canadian value set must therefore be
applied to select items of the completed QLQ-C30 to
obtain QLU-C10D utility scores. A utility index of one is
assigned to individuals whose QLQ-C30 responses indicate
they are at level 1 of all 10 domains of the QLU-C10D
(1111111111); an index of 20.15 is assigned to the worst
possible state (4444444444). For all other health states, the
utility score for individual i is calculated as follows:
QLUC10Di= 1
X10
d= 1
wdljQLUC10Ddli, ð2Þ
where w is the utility weight for each level l of domain d
of the QLU-C10D. STATA and SPSS codes for the
Canadian QLU-C10D value set are available as elec-
tronic supplemental material.
Discussion
This study determined the Canadian value set for
the QLU-C10D, a cancer-specific algorithm for calculat-
ing utilities from quality of life data collected using
the QLQ-C30. By applying the Checklist for REporting
VAluaTion StudiEs (CREATE),21 the presented
approach is considered theoretically and empirically
stronger than using approaches that map QLQ-C30
responses to other generic MAUIs.22 The results revealed
that the main contributors of an individual’s utility were
Physical Functioning, Role Functioning, and Emotional
Functioning, as well as Pain; the cancer-sensitive
domains, Nausea and Bowel Problems, also had a size-
able impact on the individual’s utility. The utility decre-
ments for the cancer-sensitive domains were generally
smaller than those of the generic domains, with the
exception of Nausea, which is a common symptom of
cancer and its treatments. However, this does not neces-
sarily limit the impact of cancer-sensitive domains in a
particular economic evaluation, as this will also be
affected by how prevalent the cancer-specific symptoms
are and the difference in symptom prevalence between
trial arms or other comparator groups. The extent to
which inclusion of cancer-specific domains, such as
Nausea and Bowel Problems, provides a more relevant
and sensitive measure of utility for cancer interventions
than generic MAUIs will depend on the clinical context,
and may be most beneficial for therapies alleviating such
symptoms or causing less symptoms due to reduced toxi-
city. Future head-to-head comparisons between the
QLU-C10D and generic MAUIs are needed to determine
the circumstances in which cancer-specific domains make
a difference to decision making.
Table 3 Instrument Scores
Mean SD Min Max
QLU-C10D 0.753 0.212 20.122 1.000
EQ-5D-5L 0.833 0.156 20.039 0.949
Kessler-10 17.91 7.68 10 50
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Initial models for both Canada and Australia revealed
some inconsistent orderings of utility decrements across
domain levels; however, the non-monotonicities differed
across countries. Canada had inconsistencies in the high-
est levels of Fatigue and Sleep; Australia had inconsis-
tencies in the lowest levels of Social Functioning and in
the highest levels of Sleep and Appetite Loss. Consistent
with the Australian study and others, constraints were
imposed to remove non-monotonicities23–27; model fit
was not compromised. For both countries, Physical
Functioning had the largest utility decrements for each
level. It is possible that the presentation of two aspects in
that domain (i.e., long walk and short walk), covering a
large range of mobility, may have amplified the impact
on the individual’s utility. The worse possible state for
both countries were negative and similar in magnitude:
Canada, 20.15; and Australia, 20.10. The conditional
logit was selected over the mixed logit results because
economic evaluation is mostly concerned with the mean
response; preference heterogeneity is a secondary con-
cern. The choice of a monotonic main-effects model for
calculating utility is readily accessible for a range of end
users, clinically interpretable and consistent with the
EORTC quality of life conceptual model.10
The QLU-C10D health state classification system was
valued using a DCE. This approach was selected over
the conventional standard gamble and time tradeoff due
to its strong theoretical measurement framework, its well
Table 4 Conditional Logit: Model 1 (Unconstrained) and Model 2 (Montonicity Imposed)
Mean Model 1—Coefficienta (Robust SE) Model 2—Coefficienta (Robust SE)
Duration Linear 0.488 (0.021)*** 0.486 (0.021)***
Physical Functioning 3 Durationa 2 20.026 (0.007)*** 20.026 (0.007)***
3 20.070 (0.008)*** 20.070 (0.008)***
4 20.118 (0.007)*** 20.117 (0.007)***
Role Functioning 3 Durationa 2 20.013 (0.006)** 20.013 (0.006)**
3 20.050 (0.006)*** 20.049 (0.006)***
4 20.071 (0.006)*** 20.070 (0.006)***
Social Functioning 3 Durationa 2 20.004 (0.006) 20.004 (0.006)
3 20.028 (0.006)*** 20.027 (0.006)***
4 20.044 (0.005)*** 20.044 (0.005)***
Emotional Functioning 3 Durationa 2 20.021 (0.006)*** 20.022 (0.006)
3 20.037 (0.006)*** 20.037 (0.006)***
4 20.060 (0.006)*** 20.060 (0.006)***
Pain 3 Durationa 2 20.014 (0.006)** 20.014 (0.006)**
3 20.060 (0.006)*** 20.059 (0.006)***
4 20.087 (0.006)*** 20.087 (0.006)***
Fatigue 3 Durationa 2 20.016 (0.005)*** 20.015 (0.005)***
3 20.027 (0.006)*** 20.026 (0.005)***
4 20.025 (0.005)*** 20.026 (0.005)***
Sleep 3 Durationa 2 20.030 (0.005)*** 20.029 (0.005)***
3 20.037 (0.006)*** 20.034 (0.005)***
4 20.032 (0.005)*** 20.034 (0.005)***
Appetite 3 Durationa 2 20.015 (0.005)*** 20.015 (0.005)***
3 20.021 (0.006)*** 20.021 (0.006)***
4 20.025 (0.005)*** 20.025 (0.005)***
Nausea 3 Durationa 2 20.036 (0.005)*** 20.036 (0.005)***
3 20.045 (0.006)*** 20.045 (0.006)***
4 20.069 (0.005)*** 20.059 (0.005)***
Bowel problems 3 Durationa 2 20.016 (0.005)*** 20.016 (0.005)***
3 20.028 (0.006)*** 20.028 (0.006)***
4 20.037 (0.005)*** 20.037 (0.005)***
Log-likelihood 222376.9 222377.55
Parameters 31 29
AIC 44815.8 44813.1
BIC 45080.5 45101.6
AIC, Akaike information criterion; BIC, Bayesian information criterion.
aThe coefficient for each level of each dimension was estimated as the interaction of that level with duration.
Levels of statistical significance: ***1%; **5%.
8 MDM Policy & Practice 00(0)
established statistically robust experimental design and
modelling methods, and its feasibility with online recruit-
ment and data collection.14,18,19 In this study, respondents
appraised choice sets containing 12 attributes. While the
relatively larger number of attributes raised concerns
regarding the cognitive burden of the respondents, innova-
tive work was conducted to have only four domains differ
in each choice set; the differing levels were identified by
the respondents’ preferred format of yellow highlighting.9
Allowing only some domains to differ across choice sets
will require respondents, who employ heuristics such as
considering a single attribute, to tradeoff between other
attributes.
There are limitations associated with this study. First,
the valuation survey sample consisted of a large number
of respondents, with quota sampling achieving popula-
tion representativeness for age, sex, and province/
territory of residence. However, when the other sociode-
mographic variables were compared (e.g., education
level, self-reported health), the study respondents’ char-
acteristics significantly differed to that of the general
population. This impact, in terms of bias to the utility
estimates, in this study is unknown, as the degree to
which each demographic variable influences respondent
preferences has not yet been determined. This question
will be assessed by the MAUCa Consortium in a future
analysis of pooled data from international valuations of
the QLU-C10D. Second, the QLU-C10D has a relatively
large number of domains, each one adding further utility
decrements. This may result in a wider range of utility
scores than utilities generated from generic MAUIs,
which may lead to different funding decisions when
incorporated in CUAs; this will be explored in the
future. Third, we did not test potential interactions
between pairs of QLU-C10D domains although we
acknowledge that they have existed; the influence of
potential interactions will be explored in the future
both quantitatively and qualitatively. Instead, we took
a more parsimonious approach for three reasons: 1)
testing all possible interactions would require an unfea-
sibly large sample size; 2) there is no conceptual frame-
work to guide the choice of a manageable subset
among the many possible interactions; and 3) the inclu-
sion of complex interactions may render the model
incomprehensible to end-users. We feel the parsimo-
nious model presented in this article is clinically inter-
pretable and likely captures much of the signal in
aggregate presences. Finally, while the construction of
the QLU-C10D health state classification system
involved pooled international data sets, the develop-
mental work for the DCE was conducted primarily in
Australia8,9 raising concerns that the methods may not
be applicable to the Canadian setting. However, the
robust results and consistent estimates, aligned with
our expectations, alleviated our concerns.
To this end, the Canadian value set is quite similar to
the Australian value set for the QLU-C10D,10 implying
that Canadians and Australians may not be different in
the way they value health states. This raises the funda-
mental question of whether there is a need to generate
distinct sets of national weights. Previous work has
Table 5 Utility Decrements Used in the QLU-C10D Utility
Algorithma
Dimension Level Utility, wdl (95% CI)
Physical Functioning 1 0
2 20.053 (20.828 to 20.024)
3 20.143 (20.175 to 20.112)
4 20.241 (20.271 to 20.212)
Role Functioning 1 0
2 20.027 (20.051 to 20.004)
3 20.101 (20.127 to 20.076)
4 20.144 (20.168 to 20.121)
Social Functioning 1 0
2 20.009 (20.031 to 0.013)
3 20.056 (20.081 to 20.032)
4 20.090 (20.112 to 20.068)
Emotional Functioning 1 0
2 20.045 (20.068 to 20.022)
3 20.076 (20.100 to 20.052)
4 20.124 (20.145 to 20.101)
Pain 1 0
2 20.029 (20.051 to 20.005)
3 20.121 (20.146 to 20.096)
4 20.179 (20.201 to 20.155)
Fatigue 1 0
2 20.032 (20.052 to 20.010)
3 20.053 (20.072 to 20.033)
4 20.053 (20.072 to 20.033)
Sleep 1 0
2 20.059 (20.080 to 20.038)
3 20.070 (20.090 to 20.050)
4 20.070 (20.090 to 20.050)
Appetite 1 0
2 20.031 (20.051 to 20.010)
3 20.043 (20.066 t0 20.020)
4 20.051 (20.072 to 20.030)
Nausea 1 0
2 20.074 (20.095 to 20.052)
3 20.093 (20.116 to 20.070)
4 20.122 (20.144 to 20.101)
Bowel problems 1 0
2 20.033 (20.054 to 20.011)
3 20.057 (20.079 to 20.032)
4 20.077 (20.097 to 20.055)
aFrom Model 2, conditional logit, monotonicity imposed.
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indicated that most of the observed differences between
national value sets stem from differences in analytical
methods rather than valuing different study popula-
tions.28 However to guide societal decisions, the
Canadian Agency for Drugs and Technologies in Health
recommends that preferences of the Canadian general
population should be the reference case.1 The Canadian
QLU-C10D value set facilitates the use of EORTC
QLQ-C30 responses to afford cancer-specific utility
weights that may be more sensitive to differences result-
ing from cancer care than a generic MAUI; this may be
more informative in guiding cancer priority setting and
resource allocation decisions in Canada. The widespread
use of the QLQ-C30 to measure quality of life outcomes
of cancer patients will enable utilities not only to be esti-
mated prospectively but also from a large number of ret-
rospective studies. We intend to conduct head-to-head
comparisons of the QLU-C10D versus generic MAUIs
assess its performance. The availability of more QALY
estimates and CUAs will enable decision makers to be
more informed when allocating resources in Canada’s
publicly funded health care system.
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